Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo de Marinis

Showing results (11-20 of 334) with videos related to

Pageof 34
Sort By:
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in second-line treatment of non-small-cell lung cancerFilippo De Marinis, Luigi De Petris
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery]Filippo De Marinis, Luigi De Petris
Therapeutics and Clinical Risk Management|October 24, 2009
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancerSerena Ricciardi, Silverio Tomao, Filippo de Marinis
European Journal of Cancer (Oxford, England : 1990)|October 8, 2025
Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma: signal or noise?Luca Bertolaccini, Filippo de Marinis, Lorenzo Spaggiari
Chinese Clinical Oncology|December 12, 2018
Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bulletsGianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Pulmonology|December 18, 2018
Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterflyAntonio Passaro, Valeria Stati, Filippo de Marinis
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
EGFR inhibitors: clinical resultsFilippo De Marinis, Fabrizio Nelli, Giuliana D'Auria
Expert Review of Anticancer Therapy|October 18, 2011
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Antonio Passaro, Enrico Cortesi, Filippo de Marinis
Clinical Lung Cancer|March 21, 2020
ReplyAntonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Pageof 34

Showing results (11-20 of 334) with videos related to

Sort By:
Pageof 34
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in second-line treatment of non-small-cell lung cancerFilippo De Marinis, Luigi De Petris
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery]Filippo De Marinis, Luigi De Petris
Therapeutics and Clinical Risk Management|October 24, 2009
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancerSerena Ricciardi, Silverio Tomao, Filippo de Marinis
European Journal of Cancer (Oxford, England : 1990)|October 8, 2025
Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma: signal or noise?Luca Bertolaccini, Filippo de Marinis, Lorenzo Spaggiari
Chinese Clinical Oncology|December 12, 2018
Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bulletsGianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Pulmonology|December 18, 2018
Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterflyAntonio Passaro, Valeria Stati, Filippo de Marinis
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
EGFR inhibitors: clinical resultsFilippo De Marinis, Fabrizio Nelli, Giuliana D'Auria
Expert Review of Anticancer Therapy|October 18, 2011
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Antonio Passaro, Enrico Cortesi, Filippo de Marinis
Clinical Lung Cancer|March 21, 2020
ReplyAntonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Pageof 34